Finoriq research workspace
Bone Biologics Corp (BBLG) Institutional Holdings & 13F Ownership
Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which. Review BBLG institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Company
- Bone Biologics Corp (BBLG)
- Ticker
- BBLG
- Market Cap
- $2M
- Latest Price
- $1.13
- Industry
- Industrial Specialties
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.